Join us Jan 30 to learn what Medical Affairs leaders learned about GenAI in 2025, and what they're funding in 2026!
Experts from Boehringer Ingelheim, Vertex & Inizio Medical, will share real-world examples of how MA teams are using GenAI to accelerate literature and evidence synthesis, support scientific content development, and improve stakeholder engagement, with the right human oversight.
What you’ll learn:
1) The AI standard for 2026: Understand 2025 Gen AI trends, what’s worked and where experts are investing budget and resources in 2026.
2) The true value of Agents: A technical look at how to use internal agents to synthesize data across labels, trial protocols, FAQs, and publications for instant, accurate insights.
3) What’s ready for pure Gen AI: A practical view of which Medical Affairs processes can be augmented today - and which still require human-led control.


Jamie DeMaria has over twenty-five years of experience in driving excellence and innovation across multiple sectors, particularly within the pharmaceutical and healthcare industries. Jamie has a background in medical affairs, clinical development, medical education, and marketing with a focus in oncology and cardiovascular medicine.

Sara has over a decade of healthcare experience—from clinical pharmacy to medical information and medical affairs. Currently, she is an Associate Director in Medical Affairs at Vertex Pharmaceuticals, where she leads medical strategy for gene therapy launches across the international region. Sara's AI journey began in early 2024 when she enrolled in a no-code tools course and built her first solution—a prescription tracking platform that eliminated patient waiting times at pharmacies. Today, as a Microsoft Copilot power user, she's applying that same mindset to medical affairs, creating an "army of agents" that handle repetitive and/or lengthy tasks such as product-related queries, congress insights capture, and reporting. Her mission is to empower and free up medical affairs teams so they can focus on what matters the most.

Phil has over 20 years of experience working in key leadership roles, both industry and agency. With oversight of the Specialized Services function of Inizio Medical (MEDiSTRAVA) Phil is responsible for medical excellence and innovation to ultimately help improve patient access to medicines. Phil is a member of the Evidence Generation Working Group for the Medical Affairs Professionals Society where he was recently awarded a MAPS Leadership Award for his commitment to progressing the field of real-world evidence.